Shots:

• Gilead to receive an up front in cash and convertible notes into Kronos equity- regulatory & commercial milestones along with royalties on sales of products emerges from the acquired programs
• Kronos to acquire the two clinical-phase assets along with the rest of Gilead’s portfolio of SYK inhibitors. The portfolio includes entospletinib- being evaluated in P-I & II study in oncology patients- and lanraplenib that has been evaluated in P-II trials for autoimmune diseases
• Kronos plans to initially focus on a biomarker-defined subset of AML patients. The focus indicates that SYK inhibition showed promising clinical activity in AML patients with cancers that overexpress the HOXA9 and MEIS1 transcription factors. Additionally- Entospletinib demonstrated positive clinical data in its early studies

  Ref: Kronos Bio | Image: Gilead